A Study of Olanzapine in Patients With Acute Agitation

Acute Agitation Clinical Trial

Official title:

A Multicenter, Randomized, Double-blind, Parallel-controlled Injection of Olanzapine in the Treatment of Acute Agitation Associated With Schizophrenia and Bipolar I Disorder.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05803642
• Other study ID #: QLG2072-301
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: March 28, 2023
• Est. completion date: July 2, 2024

Study information

• Verified date: March 2023
• Source: Qilu Pharmaceutical Co., Ltd.
• Contact: Gang Wang, PhD
• Phone: 010-58303236
• Email: adwanggang[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy and safety of intramuscular olanzapine for the treatment of acute agitation associated with schizophrenia and bipolar I mania.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 318
• Est. completion date: July 2, 2024
• Est. primary completion date: May 7, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Male and female patients between the ages of 18 to 65 years, inclusive.

2. Patients who have met DSM-5 criteria for schizophrenia and bipolar I disorder.

3. Patients who are judged to be clinically acutely agitated with a total score of = 14 on the 5 items comprising the PANSS-EC and at least one individual item score= 4 immediately before randomization.

Exclusion Criteria:

1. Patients with agitation caused by delirium, seizures, developmental delay, poisoning, etc., or withdrawal from drug abuse.

2. Patients who have had previous suicidal behavior or currently at serious risk of suicide.

3. Patients with glaucoma or at risk of angle-closure glaucoma.

4. Patients who have brain diseases such as intracranial infection, brain trauma, cerebrovascular disease, basal ganglion disease, hypoxic encephalopathy, Parkinson's disease, Parkinson's syndrome, and dementia.

5. Use of benzodiazepines, other hypnotics or short-acting antipsychotic drugs within 4 hours before randomization.

6. Treatment with psychostimulants or reserpine within one week before randomization.

7. Patients who received long-acting injections of typical or atypical antipsychotics within 2 weeks prior to randomization or within one injection interval.

8. Treatment with clozapine within 4 weeks before screening.

9. Patients with serious or unstable medical illnesses.

10. Female patients who have a positive pregnancy test at screening or are breastfeeding.

11. Patients who have participated in other clinical trials within 3 months before randomization.

Related Conditions & MeSH terms

• Acute Agitation
• Psychomotor Agitation

Intervention

Drug:
• Olanzapine
intramuscular injection, 10 mg/dose, first dose and an optional second or third dose.
• Haloperidol
intramuscular injection, 7.5 mg/dose, first dose and an optional second or third dose.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Qilu Pharmaceutical Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline to 2 hours post-first IM injection on the PANSS-EC	The PANSS-EC comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)	2 hours
Secondary	Percentage of Participants With 40% or Greater Percent Decrease in the PANSS-EC Total Score		2 hours post-first IM injection
Secondary	Proportion of participants receiving one, two, or three doses of study drug during 24-hour intramuscular treatment period		24 hours